

An Update on the Management of Diabetic Neuropathic Pain: A Few Comments

[Mohamed Amin Ghobadifar](#)

LETTERS TO EDITORS

I read with great interest the article by Nam et al. [1] entitled "Effects of nefopam on streptozotocin-induced diabetic neuropathic pain in rats", published in the Korean Journal of Pain. The authors aimed to investigate the preventive role of nefopam in the control of diabetic neuropathic pain. The authors concluded that nefopam pretreatment presented strong antiallodynic effects in diabetic rats. Although the study was well-managed - and I commend the authors for the valuable and detailed information they provided - some additional comments regarding the reduction of the hyperalgesic and allodynic actions of a potent selective μ opioid receptor agonist (remifentanyl) in diabetic conditions may be beneficial.